ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 800 • 2013 ACR/ARHP Annual Meeting

    A Strategy For Selecting Individuals With RA For Reduction Of Anti-TNF Therapy Using Combined Clinical and Ultrasound Assessment

    Christopher R. Holroyd1,2, Brian Davidson3, Sarah Bennett3, David Waghorn3, Caron Underhil3, Cyrus Cooper2, Antonia Calogeras3, Elaine M. Dennison4, Nicholas C. Harvey5, Ray Armstrong3, Stephan Gadola6 and Christopher J. Edwards7,8, 1Rheumatology, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom, 2MRC Lifecourse Epidemiology Unit, Southampton, United Kingdom, 3University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom, 4MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, United Kingdom, 5University of Southampton, MRC Lifecourse Epidemiology Unit, Southampton, United Kingdom, 6University of Southampton, Southampton, United Kingdom, 7NIHR Wellcome Trust Clinical Research Facility, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom, 8University of Southampton, Southampton, United Kingdom

    Background/Purpose: Reducing the dose of biological therapy may be possible for patients with rheumatoid arthritis (RA) who have achieved remission or low disease activity (LDA). …
  • Abstract Number: 801 • 2013 ACR/ARHP Annual Meeting

    Remaining Pain Is Common In Early RA Patients Treated With Methotrexate – Results From The EIRA Cohort and The Swedish Rheumatology Quality Register

    Reem Altawil1, Saedis Saevarsdottir2, Sara Wedren3, Lars Alfredsson4, Lars Klareskog2 and Jon Lampa1, 1Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, 2Medicine, Rheumatology unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, 3Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, 4Institute of Environmental Medicine, Karolinska Institute, Stockholm, Sweden

    Background/Purpose: Although treatment with methotrexate is often efficient in decreasing inflammation and joint destruction in RA, several patients report remaining pain at follow-up (Taylor P…
  • Abstract Number: 802 • 2013 ACR/ARHP Annual Meeting

    Tofacitinib, An Oral Janus Kinase Inhibitor: Analysis Of Malignancies Across The Rheumatoid Arthritis Clinical Program

    X. Mariette1, J. R. Curtis2, E. B. Lee3, B. Benda4, I. Kaplan5, K. Soma5, R. Chew5, J. Geier6, L. Wang7 and R. Riese5, 1Paris-Sud University, Paris, France, 2Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, 3Seoul National University, Seoul, South Korea, 4Pfizer Inc, Collegeville, PA, 5Pfizer Inc, Groton, CT, 6Pfizer Inc, New York, NY, 7Pfizer Worldwide R&D, Cambridge, MA

    Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). This analysis extended the evaluation of malignancies that occurred…
  • Abstract Number: 803 • 2013 ACR/ARHP Annual Meeting

    The Risk Of Serious Infections In Patients Receiving Rituximab For Rheumatoid Arthritis: Results From The British Society For Rheumatology Biologics Register-Rheumatoid Arthritis

    Lucía Silva-Fernández1,2, Mark Lunt3, Audrey S. Low2, Kath D. Watson3, BSRBR Control Centre Consortium2, Deborah P. Symmons2, Kimme L. Hyrich4 and On behalf of the BSRBR5, 1Rheumatology, Hospital Universitario de Guadalajara, Guadalajara, Spain, 2Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, 3Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, United Kingdom, 4Arthritis Research UK Epidemiology Unit, Manchester Academic Health Sciences Centre, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, 5British Society for Rheumatology, London, United Kingdom

    Background/Purpose: In the United Kingdom (UK), rituximab (RTX), an anti-CD20 monoclonal antibody, is currently used to treat patients with rheumatoid arthritis (RA) who have failed…
  • Abstract Number: 804 • 2013 ACR/ARHP Annual Meeting

    Tumour Necrosis Factor Inhibitors and The Risk Of Acute Coronary Syndrome In Rheumatoid Arthritis – a National Cohort Study

    Lotta Ljung1,2, Johan Askling3, Solbritt M. Rantapää-Dahlqvist4, Lennart T.H. Jacobsson5 and The ARTIS Study Group6, 1Clinical epidemiology unit, Karolinska Institutet, Stockholm, Sweden, 2Department for Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden, 3Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, 4Department for Public Health and Clinical Medicine/ Rheumatology, Umeå University, Umeå, Sweden, 5Department of Rheumatology and Inflammation Research, Institute of Medicine, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, 6Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: The high risk of ischemic heart disease (IHD) in patients with rheumatoid arthritis (RA) has been linked to inflammation and disease severity. Treatment with…
  • Abstract Number: 805 • 2013 ACR/ARHP Annual Meeting

    Good Response On Tumour Necrosis Factor Inhibitors Are Associated With a Decreased Risk Of Acute Coronary Syndromes In Patients With Rheumatoid Arthritis

    Lotta Ljung1,2, Lennart T.H. Jacobsson3, Solbritt M. Rantapää-Dahlqvist4, Johan Askling5 and The ARTIS Study Group6, 1Clinical epidemiology unit, Karolinska Institutet, Stockholm, Sweden, 2Department for Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden, 3Department of Rheumatology and Inflammation Research, Institute of Medicine, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, 4Department for Public Health and Clinical Medicine/ Rheumatology, Umeå University, Umeå, Sweden, 5Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, 6Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: Inflammatory activity, as well as traditional cardiovascular risk factors, have been suggested to underlie the increased risk of coronary disease in patients with rheumatoid…
  • Abstract Number: 806 • 2013 ACR/ARHP Annual Meeting

    Risk Of Cancer Recurrence Or New Tumors In RA Patients With Prior Malignancies Treated With Various Biologic Agents

    Anja Strangfeld1, Dagmar Pattloch2, Peter Herzer3, Edmund Edelmann4, Silke Zinke5, Martin Aringer6, Joachim Listing7 and Angela Zink8, 1Programme Area Epidemiology, German Rheumatism Research Center, a Leipniz Institute, Berlin, Germany, 2Programm Area Epidemiologiy, German Rheumatism Research Center, Berlin, Berlin, Germany, 3University of Munich, Munich, Germany, 4Rheumatologist, Bad Aibling, Germany, 5Rheumatological Office, Berlin, Germany, 6Rheumatology, Medicine III, University Clinical Center Technical University of Dresden, Dresden, Germany, 7German Rheumatism Research Center, Berlin, Germany, 8German Rheumatism Research Centre and Charité University Medicine, Berlin, Germany

    Background/Purpose: If patients with rheumatoid arthritis (RA) have a history of malignancy, the choice of treatment is an important clinical question. The aim is to…
  • Abstract Number: 807 • 2013 ACR/ARHP Annual Meeting

    Perioperative Use Of Anti-Rheumatic Agents Does Not Increase Early Postoperative Infection Risks: A Veteran Affairs’ Administrative Database Study

    Zaki AbouZahr1, Andrew Spiegelman2, Maria Cantu3 and Bernard Ng4, 1Baylor College of Medicine, Houston, TX, 2Michael E DeBakey Veteran Affairs Medical Center, Houston, TX, 3Baylor College Of Medicine, Houston, TX, 4Michael E. DeBakey VA Medical Center, Houston, TX

    Background/Purpose: Evidences for perioperative management of disease modifying anti-rheumatic drugs (DMARDs) and biologic agents (BA) are sparse, and limited mainly to methotrexate & specific surgeries…
  • Abstract Number: 768 • 2013 ACR/ARHP Annual Meeting

    Inhibition Of X-Box Binding Protein 1 (XBP1) Is Chondroprotective By Promoting Autophagy and Inhibiting Catabolic Responses

    Ru L. Bryan1, Robert Terkeltaub2 and Ramon Serrano3, 1Medicine-Rheumatology, VA Medical Center/University of California San Diego, San Diego, CA, 2Medicine-Rheumatology, VA Medical Ctr/University of California San Diego, San Diego, CA, 3VA Medical Center, San Diego, CA

    Background/Purpose: Chondrocyte stress responses to biomechanical injury and joint inflammation, and associated changes in differentiation and function, provide a foundation upon which cartilage injury and…
  • Abstract Number: 769 • 2013 ACR/ARHP Annual Meeting

    Synovial Wnt and WISP1 Expression Induces Expression Of Cartilage-Degrading Metalloproteinases In The Synovium

    Martijn H. van den Bosch1, Arjen B. Blom1, Sylvia W. Suen2, Anke E. van Erp2, Fons A. van de Loo3, Esmeralda N. Blaney Davidson1, Peter M. van der Kraan3, Peter L. van Lent4 and Wim B. van den Berg5, 1Rheumatology Research & Advanced Therapeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 2Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands, 3Rheumatology Research and Advanced Therapeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 4Rheumatology Research & Advanced Therpeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 5Rheumatology Research and Advanced Therapeutics, Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands

    Background/Purpose: Although many osteoarthritis (OA) patients show significant synovial involvement, consequences are largely unknown. Previously, we found strong upregulation of Wnts 2b and 16 and…
  • Abstract Number: 770 • 2013 ACR/ARHP Annual Meeting

    Suppressor Of Cytokine Signaling-3 Is a Critical Regulator Of gp130 Cytokine Signaling In Articular Chondrocytes

    Xiao Liu1,2, Kate E Lawlor1,2, Ben A Croker1 and Ian P Wicks1,2,3, 1Inflammation Division, Walter & Eliza Hall Institute of Medical Research, Parkville, Australia, 2Department of Medical Biology, University of Melbourne, Parkville, Australia, 3Department of Rheumatology, The Royal Melbourne Hospital, Melbourne, Australia

    Background/Purpose: Cartilage damage is a key feature of inflammatory and degenerative arthritis and an important determinant of patient outcomes. Chondrocytes are the only cells in…
  • Abstract Number: 771 • 2013 ACR/ARHP Annual Meeting

    The S100A9 Inhibitor Paquinimod (ABR-215757) Reduces Synovial Activation, Osteophyte Formation and Cartilage Damage In Experimental Osteoarthritis

    Rik Schelbergen1, Arjen B. Blom1, Tomas Leanderson2, Helena Eriksson3, Wim B. van den Berg4 and Peter L.E.M. van Lent1, 1Rheumatology Research & Advanced Therapeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 2Immunology Group, Lund University, Lund, Sweden, 3BioScience, Active Biotech AB, Lund, Sweden, 4Rheumatology Research and Advanced Therapeutics, Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands

    Background/Purpose: Synovial activation is present in a large subset of osteoarthritis (OA) patients and it is thought to play an important role in the development…
  • Abstract Number: 772 • 2013 ACR/ARHP Annual Meeting

    Neovascularization and CD15s Influence Long Distance Migration Of Synovial Fibroblasts From Patients With Rheumatoid Arthritis

    Birgit Zimmermann1, Sina Köppert1, Stephanie Lefèvre1, Stefan Rehart2, Ulf Müller-Ladner1 and Elena Neumann3, 1Internal Medicine and Rheumatology, Justus-Liebig-University of Gießen, Kerckhoff-Klinik, Bad Nauheim, Germany, 2Orthopedics and Trauma Surgery, Markus-Hospital, Frankfurt, Germany, 3Department of Internal Medicine and Rheumatology, Justus-Liebig-University of Gießen, Kerckhoff-Klinik, Bad Nauheim, Germany

    Background/Purpose: Rheumatoid arthritis (RA) synovial fibroblasts (SF) are central cells of cartilage destruction and neoangiogenesis. RASF show an increased migratory potential in the synovium towards…
  • Abstract Number: 773 • 2013 ACR/ARHP Annual Meeting

    Adioponectin-Induced p38 MAPK and AMPK Pathways In Rheumatoid Arthritis Synovial Fibroblasts Are Adiponectin Isoform Dependent

    Kiran Khawaja1, Klaus W. Frommer1, Stefan Rehart2, Ulf Müller-Ladner1 and Elena Neumann3, 1Internal Medicine and Rheumatology, Justus-Liebig-University of Gießen, Kerckhoff-Klinik, Bad Nauheim, Germany, 2Orthopedics and Trauma Surgery, Markus-Hospital, Frankfurt, Germany, 3Department of Internal Medicine and Rheumatology, Justus-Liebig-University of Gießen, Kerckhoff-Klinik, Bad Nauheim, Germany

    Background/Purpose: Adiponectin, a C1q/tumour necrosis factor (TNF) homologue, was previously known to be secreted by adipocytes. Additionaly, it was found to be synthesized by other…
  • Abstract Number: 774 • 2013 ACR/ARHP Annual Meeting

    Citrullination Of ENA-78/CXCL5 Changes Its Receptor Affinity From CXCR2 To CXCR1 and Induces Monocyte Migration

    Ken Yoshida1, Alisa E. Koch1,2, Ray A. Ohara3, Phillip L. Campbell1, M. Asif Amin1, David A. Fox1 and Jeffrey H. Ruth4, 1Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, 2VA Medical Service, Ann Arbor, MI, 3University of Michigan Medical School, Ann Arbor, MI, 4Internal Medicine, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI

    Background/Purpose: We previously showed that citrullinated epithelial-derived neutrophil-activating peptide 78/CXCL5 (citENA-78/CXCL5) was significantly higher in rheumatoid arthritis (RA) synovial fluids (SFs) compared to osteoarthritis (OA)…
  • « Previous Page
  • 1
  • …
  • 2195
  • 2196
  • 2197
  • 2198
  • 2199
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology